[BMJ Publishing Group Ltd and European League Against Rheumatism Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019 - ()] SATURDAY, 15 JUNE 2019 - SAT0161 SUSTAINED MODERATE DISEASE ACTIVITY (SMDA) IN RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGIC THERAPIES IS ASSOCIATED WITH 5 YEARS FUNCTIONAL LIMITATION AND SERIOUS ADVERSE EVENTSDEVELOPMENT; EVIDENCE TO SUPPORT TREAT-TO-TARGET APPROACH FOR PATIENTS IN SMDA AND ESPECIALLY THOSE IN HIGH SMDA